References

Engineered virus-like nanoparticles enable multimodal protein degradation for enhanced tumor therapy

10.1002/adma.202507608 · ExternalCitation · doi-reference

Brush-on-brush architecture enables durable and reversible aptamer therapeutics with minimal peg associated immunogenicity

10.1002/adma.73308 · ExternalCitation · doi-reference

Antitumor effect of anti-c-myc aptamer-based protac for degradation of the c-myc protein

10.1002/advs.202309639 · ExternalCitation · doi-reference

Drugtamer-protac conjugation strategy for targeted protac delivery and synergistic antitumor therapy

10.1002/advs.202401623 · ExternalCitation · doi-reference

The chemical biology of aptamers

10.1002/anie.200804643 · ExternalCitation · doi-reference

Aptamer blocking strategy inhibits SARS-COV-2 virus infection

10.1002/anie.202100225 · ExternalCitation · doi-reference

Aptamer-protac conjugates (APCs) for tumor-specific targeting in breast cancer

10.1002/anie.202107347 · ExternalCitation · doi-reference

Aptamer-lytacs for targeted degradation of extracellular and membrane proteins

10.1002/anie.202218106 · ExternalCitation · doi-reference

Targeted degradation of ZBP1 with covalent protacs for anti-inflammatory treatment of infections

10.1002/anie.202423524 · ExternalCitation · doi-reference

Kinetic ITC of DNA aptamers binding for small molecules and implications for binding assays and biosensors

10.1002/cbic.202400225 · ExternalCitation · doi-reference

Selective degradation of the p53-r175h oncogenic hotspot mutant by an RNA aptamer-based protac

10.1002/ctm2.1191 · ExternalCitation · doi-reference

Advancing design strategy of protacs for cancer therapy

10.1002/mco2.70258 · ExternalCitation · doi-reference

Utilizing aptamers in targeted protein degradation strategies for disease therapy

10.1002/path.6422 · ExternalCitation · doi-reference

Bioorthogonal aptamer-attec conjugates for degradation of alpha-synuclein via autophagy-lysosomal pathway

10.1002/smll.202306760 · ExternalCitation · doi-reference

Aptamer-functionalized hydrogels: An emerging class of biomaterials for protein delivery, cell capture, regenerative medicine, and molecular biosensing

10.1002/wnan.1731 · ExternalCitation · doi-reference

Aptamer-based molecular recognition for biosensor development

10.1007/s00216-010-3987-y · ExternalCitation · doi-reference

The host immune response in respiratory virus infection: Balancing virus clearance and immunopathology

10.1007/s00281-016-0558-0 · ExternalCitation · doi-reference

Calcineurin is a common target of cyclophilin-cyclosporin a and fkbp-fk506 complexes

10.1016/0092-8674(91)90124-h · ExternalCitation · doi-reference

Aptamer-based applications in delivering cancer gene therapies and beyond: State of the art and the missing links to clinical translation

10.1016/j.addr.2025.115639 · ExternalCitation · doi-reference

Covalent chemistry in targeted protein degradation

10.1016/j.addr.2026.115777 · ExternalCitation · doi-reference

Discovery of novel exceptionally potent and orally active c-met protacs for the treatment of tumors with met alterations

10.1016/j.apsb.2023.01.014 · ExternalCitation · doi-reference

Overview of epigenetic degraders based on protac, molecular glue, and hydrophobic tagging technologies

10.1016/j.apsb.2023.09.003 · ExternalCitation · doi-reference

Influenza virus z-RNAs induce zbp1-mediated necroptosis

10.1016/j.cell.2020.02.050 · ExternalCitation · doi-reference

The role of reversible and irreversible covalent chemistry in targeted protein degradation

10.1016/j.chembiol.2021.03.005 · ExternalCitation · doi-reference

DAI/ZBP1/DLM-1 complexes with rip3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vira

10.1016/j.chom.2019.09.004 · ExternalCitation · doi-reference

As1411 aptamer based nanomaterials: A novel approach for breast cancer therapy

10.1016/j.ijbiomac.2025.145125 · ExternalCitation · doi-reference

An innovative ricin-degrading antidote based on aptamer-autophagy-tethering compound strategy

10.1016/j.ijbiomac.2026.151604 · ExternalCitation · doi-reference

Targeted protein degradation in autoimmune diseases: From mechanisms to therapeutic breakthroughs

10.1016/j.jaut.2025.103475 · ExternalCitation · doi-reference

Aptamers in drug delivery development

10.1016/j.mattod.2025.06.020 · ExternalCitation · doi-reference

Selection of metastatic breast cancer cell-specific aptamers for the capture of CTCs with a metastatic phenotype by cell-selex

10.1016/j.omtn.2018.07.008 · ExternalCitation · doi-reference

DNA aptamers targeting bace1 reduce amyloid levels and rescue neuronal deficiency in cultured cells

10.1016/j.omtn.2019.02.025 · ExternalCitation · doi-reference

Base-modified aptamers obtained by cell-internalization selex facilitate cellular uptake of an antisense oligonucleotide

10.1016/j.omtn.2020.11.016 · ExternalCitation · doi-reference

Deepaptamer: Advancing high-affinity aptamer discovery with a hybrid deep learning model

10.1016/j.omtn.2024.102436 · ExternalCitation · doi-reference

Targeted clearance of mitochondria by an autophagy-tethering compound (attec) and its potential therapeutic effects

10.1016/j.scib.2023.10.021 · ExternalCitation · doi-reference

An engineered DNA aptamer-based protac for precise therapy of p53-r175h hotspot mutant-driven cancer

10.1016/j.scib.2024.05.017 · ExternalCitation · doi-reference

Nanotechnology and aptamers: Applications in drug delivery

10.1016/j.tibtech.2008.04.006 · ExternalCitation · doi-reference

Emerging new concepts of degrader technologies

10.1016/j.tips.2020.04.005 · ExternalCitation · doi-reference

Leveraging aptamers for targeted protein degradation

10.1016/j.tips.2023.05.008 · ExternalCitation · doi-reference

Tdp-43 and fus in amyotrophic lateral sclerosis and frontotemporal dementia

10.1016/s1474-4422(10)70195-2 · ExternalCitation · doi-reference

Fragment linker prediction using the deep encoder-decoder network for protacs drug design

10.1021/acs.jcim.2c01287 · ExternalCitation · doi-reference

Inducible degradation of oncogenic nucleolin using an aptamer-based protac

10.1021/acs.jmedchem.2c01557 · ExternalCitation · doi-reference

Recent progress in aptamer discoveries and modifications for therapeutic applications

10.1021/acsami.0c05750 · ExternalCitation · doi-reference

Aptamer-based targeted protein degradation

10.1021/acsnano.2c10379 · ExternalCitation · doi-reference

A cyclized bivalent aptamer-based protein degrader targeting receptor tyrosine kinases overcomes resistance to inhibitors in lung cancer

10.1021/acsnano.5c03120 · ExternalCitation · doi-reference

Phototriggered lytac: Photoactive bispecific aptamer chimera enhances targeted degradation of membrane protein through regulating cell autophagy

10.1021/jacs.5c05456 · ExternalCitation · doi-reference

Efficient targeted degradation via reversible and irreversible covalent protacs

10.1021/jacs.9b13907 · ExternalCitation · doi-reference

Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection

10.1021/nn204165v · ExternalCitation · doi-reference

FDA approves second RNA aptamer

10.1038/d41573-023-00148-z · ExternalCitation · doi-reference

Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53

10.1038/leu.2017.325 · ExternalCitation · doi-reference

Aptamers as targeted therapeutics: Current potential and challenges

10.1038/nrd.2016.199 · ExternalCitation · doi-reference

Pegaptanib, a targeted anti-vegf aptamer for ocular vascular disease

10.1038/nrd1955 · ExternalCitation · doi-reference

Structural mechanism of insulin receptor activation by a dimeric aptamer agonist

10.1038/s12276-025-01494-1 · ExternalCitation · doi-reference

Targeted protein degradation: Mechanisms, strategies and application

10.1038/s41392-022-00966-4 · ExternalCitation · doi-reference

Myc and kras cooperation: From historical challenges to therapeutic opportunities in cancer

10.1038/s41392-024-01907-z · ExternalCitation · doi-reference

Targeted protein degradation: Advances in drug discovery and clinical practice

10.1038/s41392-024-02004-x · ExternalCitation · doi-reference

Degradation of lipid droplets by chimeric autophagy-tethering compounds

10.1038/s41422-021-00532-7 · ExternalCitation · doi-reference

The autotac chemical biology platform for targeted protein degradation via the autophagy-lysosome system

10.1038/s41467-022-28520-4 · ExternalCitation · doi-reference

DNA nanoflower oligo-protac for targeted degradation of fus to treat neurodegenerative diseases

10.1038/s41467-025-60039-2 · ExternalCitation · doi-reference

Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers

10.1038/s41551-018-0343-6 · ExternalCitation · doi-reference

Lessons learned in linking protacs from discovery to the clinic

10.1038/s41570-025-00784-6 · ExternalCitation · doi-reference

Ras-targeted therapies: Is the undruggable drugged?

10.1038/s41573-020-0068-6 · ExternalCitation · doi-reference

Advances in targeting ‘undruggable’ transcription factors with small molecules

10.1038/s41573-021-00199-0 · ExternalCitation · doi-reference

Protac targeted protein degraders: The past is prologue

10.1038/s41573-021-00371-6 · ExternalCitation · doi-reference

Targeted protein degradation: From mechanisms to clinic

10.1038/s41580-024-00729-9 · ExternalCitation · doi-reference

Allele-selective lowering of mutant htt protein by htt-lc3 linker compounds

10.1038/s41586-019-1722-1 · ExternalCitation · doi-reference

Lysosome-targeting chimaeras for degradation of extracellular proteins

10.1038/s41586-020-2545-9 · ExternalCitation · doi-reference

Lytacs that engage the asialoglycoprotein receptor for targeted protein degradation

10.1038/s41589-021-00770-1 · ExternalCitation · doi-reference

Proteolysis-targeting chimera (protac) delivery system: Advancing protein degraders towards clinical translation

10.1039/d1cs00762a · ExternalCitation · doi-reference

Translational pk-pd for targeted protein degradation

10.1039/d2cs00114d · ExternalCitation · doi-reference

Protacs: Past, present and future

10.1039/d2cs00193d · ExternalCitation · doi-reference

Applications of covalent chemistry in targeted protein degradation

10.1039/d2cs00362g · ExternalCitation · doi-reference

Protein-targeted aptamers in liquid biopsy: From efficient screening to precise cancer diagnosis

10.1039/d5an00864f · ExternalCitation · doi-reference

Stability modification of therapeutic aptamers: From biostability bottlenecks to nuclease-resistant construct design

10.1039/d6cb00062b · ExternalCitation · doi-reference

Vepdegestrant, a protac estrogen receptor degrader, in advanced breast cancer

10.1056/nejmoa2505725 · ExternalCitation · doi-reference

Protacs: Chimeric molecules that target proteins to the skp1-cullin-f box complex for ubiquitination and degradation

10.1073/pnas.141230798 · ExternalCitation · doi-reference

The z-nucleic acid sensor ZBP1 in health and disease

10.1084/jem.20221156 · ExternalCitation · doi-reference

Delivery, effect on cell viability, and plasticity of modified aptamer constructs

10.1089/nat.2015.0592 · ExternalCitation · doi-reference

Intracellular trafficking and endosomal release of oligonucleotides: What we know and what we don’t

10.1089/nat.2018.0727 · ExternalCitation · doi-reference

The bace1-specific DNA aptamer a1 rescues amyloid-β pathology and behavioral deficits in a mouse model of alzheimer’s disease

10.1089/nat.2019.0812 · ExternalCitation · doi-reference

Proteolysis-targeting chimeras in drug development: A safety perspective

10.1111/bph.15014 · ExternalCitation · doi-reference

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage t4 DNA polymerase

10.1126/science.2200121 · ExternalCitation · doi-reference

SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer

10.1158/0008-5472.can-16-2300 · ExternalCitation · doi-reference

Aptamers as an approach to targeted cancer therapy

10.1186/s12935-024-03295-4 · ExternalCitation · doi-reference

Taking the myc out of cancer: Toward therapeutic strategies to directly inhibit c-myc

10.1186/s12943-020-01291-6 · ExternalCitation · doi-reference

Pathogenesis of fus-associated als and ftd: Insights from rodent models

10.1186/s40478-016-0358-8 · ExternalCitation · doi-reference

10.1371/journal.pone.0043836

10.1371/journal.pone.0043836 · ExternalCitation · doi-reference

A novel ph-sensitive multifunctional DNA nanomedicine: An enhanced and harmless gd2 aptamer-mediated strategy for guiding neuroblastoma antitumor therapy

10.2147/ijn.s302450 · ExternalCitation · doi-reference

Discovery of aptamers and the acceleration of the development of targeting research in ophthalmology

10.2147/ijn.s418115 · ExternalCitation · doi-reference

10.3390/cancers13164088

10.3390/cancers13164088 · ExternalCitation · doi-reference

10.3390/ijms18081683

10.3390/ijms18081683 · ExternalCitation · doi-reference

10.3390/ijms22073605

10.3390/ijms22073605 · ExternalCitation · doi-reference

Extracellular and membrane-targeted protein degradation (emtpd): Mechanisms, design frameworks, and therapeutic opportunities

10.59717/j.xinn-drugdisc.2026.100024 · ExternalCitation · doi-reference

A novel small-molecule protac selectively promotes tau clearance to improve cognitive functions in alzheimer-like models

10.7150/thno.55680 · ExternalCitation · doi-reference

Targeted degradation of vegf with bispecific aptamer-based lytacs ameliorates pathological retinal angiogenesis

10.7150/thno.98467 · ExternalCitation · doi-reference